Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Read More
Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Read More
Major Adverse Events of Anti-HER2 Therapies
Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
Read More
HER2-Targeted Therapies in NSCLC
Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Read More
Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Read More
Testing Patients with NSCLC for HER2 Mutations
Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
Read More
Approaches to Biomarker Testing in NSCLC
Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.
Read More
Biomarker Testing in NSCLC: Clinical Scenario
A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.
Read More
Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer
March 17th 2022Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.
Read More
Testing for Gene Alterations and Protein Expression in Advanced NSCLC
October 11th 2021Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.
Read More
Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC
October 11th 2021An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.
Read More